Dyslipidemia in renal disease: causes, consequences and treatment

Joana Mesquita; Ana Varela; José Luís Medina

doi:10.1016/j.endonu.2010.06.003

Dyslipidemia in renal disease: causes, consequences and treatment

Endocrinol Nutr. 2010 Nov;57(9):440-8. doi: 10.1016/j.endonu.2010.06.003. Epub 2010 Sep 17.

Authors

Joana Mesquita¹, Ana Varela, José Luís Medina

Affiliation

¹ Endocrinology Department, Hospital de São João-EPE, Portugal. joanamesquita1@gmail.com

PMID: 20850395
DOI: 10.1016/j.endonu.2010.06.003

Abstract

The prevalence of chronic renal insufficiency and its complications, including dyslipidemia, is increasing. Although the characteristics of dyslipidemia in chronic renal insufficiency and its pathophysiology are well known, its cardiovascular and renal impact and the most effective therapeutic approach are poorly defined.

Publication types

Review

MeSH terms

Cardiovascular Diseases / etiology
Cardiovascular Diseases / therapy
Dyslipidemias / etiology*
Dyslipidemias / therapy*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Renal Insufficiency, Chronic / complications*
Renal Insufficiency, Chronic / metabolism

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors